Added to YB: 2026-10-14
Pitch date: 2026-10-12
RXST [bullish]
RxSight, Inc.
-0.21%
current return
Author Info
Scalper's Lounge has a background in mid-office roles and now shares stock ideas in their newsletter. Sign up for the newsletter.
Company Info
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States.
Market Cap
$200.1M
Pitch Price
$4.68
Price Target
N/A
Dividend
N/A
EV/EBITDA
-0.04
P/E
-4.22
EV/Sales
0.01
Sector
Health Care Equipment and Supplies
Category
value
RxSight: commercial medtech trading below net cash with a new CEO and new Alcon partnership
RXST (hold): RxSight trades below net cash, with more than $250M of cash versus a ~$200M market cap and roughly five years of runway; its adjustable cataract lens retains a niche in complex/LASIK-treated eyes, while the Alcon EDOF collaboration provides upside. The current ~1.5% position will be managed nimbly: Q2 lens units fell 9% y/y, competition is improving, annual losses approach $50M, and RIS could ultimately make LAL technology obsolete.
Read full article (6 min)